Multiplex Assay Kit for Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) ,etc. by FLIA (Flow Luminescence Immunoassay)

SCCA2; PI11; SPB4; Leupin; Serpin Peptidase Inhibitor,Clade B,Member 4; Peptidase Inhibitor 11

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 97-105 101
EDTA plasma(n=5) 91-99 94
heparin plasma(n=5) 83-93 89
sodium citrate plasma(n=5) 93-101 97

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 98-105% 78-90% 82-89% 88-101%
EDTA plasma(n=5) 89-101% 97-105% 93-101% 83-95%
heparin plasma(n=5) 94-101% 83-97% 83-104% 93-105%
sodium citrate plasma(n=5) 87-95% 93-101% 94-102% 95-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:SERPINB4) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Diseases of the Esophagus An expression of squamous cell carcinoma antigen 2 in peripheral blood within the different stages of esophageal carcinogenesis PubMed: 19125792
Asian Journal of Oncology Role of squamous cell carcinoma antigen in monitoring of treatment response of cervical and vaginal malignancies www.asjo.in
25 Squamous cell carcinoma antigen reproducible marker and its clinicopathological correlation with preinvasive and invasive cervical cancer DOI: 10.4103/ccij.ccij_43_17
Head & neck Combination of serum squamous cell carcinoma antigens 1 and 2 as potential diagnostic marker for sinonasal squamous cell carcinoma and inverted papilloma Pubmed: 30376194
Journal of Cosmetic Dermatology Measurement of squamous cell carcinoma antigen 2 in lichen planus patients Pubmed: 31815365
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPA159Mu01 Recombinant Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) Positive Control; Immunogen; SDS-PAGE; WB.
RPA159Mu02 Recombinant Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) Positive Control; Immunogen; SDS-PAGE; WB.
PAA159Mu01 Polyclonal Antibody to Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) WB
PAA159Mu02 Polyclonal Antibody to Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) WB; IHC; ICC; IP.
LAA159Mu71 Biotin-Linked Polyclonal Antibody to Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) WB; IHC; ICC.
SEA159Mu ELISA Kit for Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA159Mu Multiplex Assay Kit for Serpin Peptidase Inhibitor,Clade B,Member 4 (SERPINB4) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.